American College of Cardiology Announces Late-Breaking Clinical Trials

The American College of Cardiology announced the lineup of late-breaking clinical trials for its upcoming annual meeting in Washington, DC. The opening session will include the most eagerly anticipated trials– the main results of Symplicity HTN-3 and the  comparison of Corevalve and surgery in high risk patients. Subsequent sessions will include several phase 3 trials of  PCSK9 inhibitors. Here is the complete list of trials:

Click here to read the full post on Forbes.

 

Leave a Reply

%d bloggers like this: